LEADER 01669nam  2200361   450 
001 9910674024603321
005 20230628161919.0
024 7 $a10.3390/books978-3-03842-876-3
035   $a(CKB)4100000003273635
035   $a(NjHacI)994100000003273635
035   $a(EXLCZ)994100000003273635
100   $a20230628d2018      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aMonoclonal Antibodies /$fedited by Christian Klein
210  1$aBasel, Switzerland :$cMDPI - Multidisciplinary Digital Publishing Institute,$d2018.
215   $a1 online resource (238 pages) $cillustrations
311   $a3-03842-875-2 
320   $aIncludes bibliographical references.
330   $aMonoclonal antibodies are established in clinical practice for the treatment of cancer, and autoimmune and infectious diseases. The first generation of antibodies has been dominated by classical IgG antibodies, however, in the last decade, the field has advanced, and, nowadays, a large proportion of antibodies in development have been engineered. This Special Issue on "Monoclonal Antibodies" includes original manuscripts and reviews covering various aspects related to the discovery, analytical characterization, manufacturing and development of therapeutic and engineered antibodies.
606   $aMonoclonal antibodies
615  0$aMonoclonal antibodies.
676   $a616.0793
702   $aKlein$b Christian
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910674024603321
996   $aMonoclonal antibodies$9708694
997   $aUNINA